MannKind Corp. and United Therapeutics have reached a milestone in their licensing and collaboration agreement with a new drug application submitted to the U.S. Food and Drug Administration for the partnership’s pulmonary arterial hypertension treatment.

Called Tyvaso DPI, the inhalable dry powder of treprostinil (TreT) uses MannKind’s inhalation technology first commercialized for delivery of Afrezza, the Westlake Village company’s inhalable insulin.

The partnership is also working on a Bluetooth-connected accessory for the Tyvaso DPI inhaler called BluHale, which monitors inhaler use through a mobile application.


Subscribe to get the full story.

Are you a subscriber? Sign In